- ACTengine® IMA203 GEN1 TCR-T
targeting PRAME showed 50% (6/12) confirmed ORR in melanoma
patients with median duration of response (mDOR) not reached at
median follow-up of 14.4 months including responses ongoing at
>15 months after infusion; IMA203 GEN1 continues to be well
tolerated; company is targeting registration-enabling Phase 2 trial
in melanoma to commence in 2024; update on the clinical development
plan in 1Q 2024
- First clinical data on ACTengine®
IMA203CD8 GEN2 TCR-T targeting PRAME demonstrated 56% (5/9)
confirmed ORR with manageable tolerability while showing enhanced
pharmacology and differentiated response pattern with the longest
ongoing response at >12 months
- Signal finding in non-melanoma
indications started, including ovarian cancer, uterine cancer,
NSCLC, triple-negative breast cancer, preferentially with IMA203CD8
GEN2
- TCER® IMA402: First patient dosed
in Phase 1/2 clinical trial evaluating the company’s
next-generation half-life extended TCR Bispecific program targeting
PRAME
- Immatics and Moderna announced a
strategic multi-platform collaboration combining Immatics’ target
and TCR platforms with Moderna’s cutting-edge mRNA technology to
develop innovative oncology therapeutics; Immatics received $120
million upfront payment, and the total deal volume could exceed
$1.7 billion
- $35 million equity investment from
Bristol Myers Squibb
- Cash and cash equivalents as well
as other financial assets amount to $388 million, as of September
30, 2023, not including $120 million upfront payment received by
Moderna; summing up to more than $500 million, projected cash
runway remains well into 2026
Tuebingen, Germany and Houston, TX,
November 14, 2023 – Immatics N.V. (NASDAQ: IMTX;
“Immatics”), a clinical-stage biopharmaceutical company active in
the discovery and development of T cell-redirecting cancer
immunotherapies, today provided a business update and reported
financial results for the quarter ended September 30, 2023.
“Immatics has had a strong quarter and made
steady progress both in terms of the advancement of our clinical
programs and in business development. This includes an equity
investment by Bristol Myers Squibb, the initiation of a long-term
strategic collaboration with Moderna, the first patient dosed in
our TCER® IMA402 clinical trial and now the data update on our
ACTengine® IMA203 GEN1 and GEN2 TCR-T monotherapies that
demonstrated the potential for durable clinical benefit for
advanced-stage solid cancer patients,” said Harpreet Singh, Ph.D.,
CEO and Co-Founder of Immatics. “As we continue to move IMA203
towards a pivotal trial next year, in conjunction with over $500
million on our balance sheet, we are well positioned for 2024. We
look forward to providing first clinical data for our two
next-generation TCR Bispecifics programs, IMA401 targeting MAGEA4/8
and IMA402 targeting PRAME, among other updates.”
Third Quarter 2023 and Subsequent Company
Progress
Adoptive Cell Therapy Programs
ACTengine® IMA203
On November 8, 2023, the company announced
interim data from the ongoing Phase 1 trial with ACTengine® IMA203
in patients with recurrent and/or refractory solid cancers (data
cut-off September 30, 2023). The update was focused on IMA203 GEN1
in melanoma patients at the recently defined recommended Phase 2
dose (RP2D, 1.0-10x109 total TCR-T cells) and the first clinical
data for IMA203CD8 GEN2.
IMA203 GEN1 in melanoma patients treated
at RP2D in Phase 1a and Cohort A:
- Interim update
on first-generation IMA203 that includes functional CD8 T cells
targeting an HLA-A*02-presented peptide derived from PRAME.
- Safety
population (N=16 patients infused): IMA203 GEN1 monotherapy
continues to be well tolerated. All 16 patients experienced
cytopenia (Grade 1-4) associated with lymphodepletion as expected.
Patients had mostly mild-moderate cytokine release syndrome (CRS),
of which 10 patients (63%) had Grade 1, and 5 patients (31%) Grade
2 and 1 patient (6%) Grade 3 CRS. One non-serious, mild (Grade 1)
immune effector cell associated neurotoxicity syndrome (ICANS) was
observed. No dose-dependent increase of CRS, no dose-limiting
toxicities (DLTs) and no IMA203-related death was observed. The
safety profile for non-melanoma patients treated with IMA203 GEN1
was generally consistent with safety in the melanoma subset.
- Efficacy
population (N=13 patients infused with at least one available
response assessment): Patients received a median total infused dose
of 1.73x109 IMA203 TCR-T cells (range 1.07-5.12x109 TCR-T cells).
Most patients were heavily pre-treated with a median of 4 lines of
systemic therapies, thereof a median of 2 lines of checkpoint
inhibitors; all 8 cutaneous melanoma patients were checkpoint
inhibitor-refractory and 5 of 8 were BRAF
inhibitor-pretreated.
- 50% (6/12)
confirmed objective response rate (cORR) and 62% (8/13) initial ORR
(RECIST 1.1).
- Durability of
responses ongoing beyond 12 months in one patient and beyond 15
months in two patients following infusion.
- Median duration
of response (mDOR) was not reached (min 2.2+ months, max 14.7+
months) at a median follow-up (mFU) of 14.4 months.
- Development strategy: Immatics has
recently received Regenerative Medicine Advanced Therapy (RMAT)
designation from the FDA for IMA203 GEN1 in multiple
PRAME-expressing cancers, including cutaneous and uveal melanoma,
and is now targeting a registration-enabling Phase 2 trial in
cutaneous melanoma potentially bundled with uveal melanoma in 2024.
Discussions with FDA to align on patient population, trial design
and CMC aspects of the planned Phase 2 trial are ongoing. An update
on the clinical development plan is expected in the first quarter
of 2024.
IMA203CD8 GEN2 in Cohort C:
- First clinical data on
second-generation IMA203CD8 that includes functional CD8 and CD4 T
cells targeting an HLA-A*02-presented peptide derived from
PRAME.
- 12 patients in this basket trial
were infused with IMA203CD8 GEN2 across DL3 (0.2-0.48x109 TCR-T
cells/m2 BSA), DL4a (0.481-0.8x109 TCR-T cells/m2 BSA) and DL4b
(0.801-1.2x109 TCR-T cells/m2) with a median total infused dose of
1.17x109 IMA203CD8 TCR-T cells (range 0.64-2.05x109 TCR-T
cells).
- All patients were heavily
pre-treated with a median of 3 lines of systemic therapies.
- IMA203CD8 GEN2 exhibits a
manageable tolerability profile. All patients experienced cytopenia
(Grade 1-4) associated with lymphodepletion as expected. 11 out of
12 patients (92%) experienced a cytokine release syndrome (CRS), of
which 8 patients (67%) had Grade 1 or 2 CRS, 2 patients (17%) had
Grade 3 CRS (both treated at DL4b) and 1 patient (8%) had a Grade 4
CRS (treated at DL4b). The latter patient also had a reported Grade
4 neurotoxicity. No ICANS or neurotoxicity was reported for the
other patients. No IMA203CD8-related deaths were observed.
Dose-limiting toxicities (DLTs) were reported for 2 of 4 patients
treated at DL4b. No DLT was reported for all 4 patients treated at
DL3, or all 4 patients treated at DL4a. DL4a dose cohort is
ongoing.
- Initial clinical activity was
observed during dose escalation across all dose levels with a cORR
of 56% (5/9) and initial ORR of 58% (7/12) (RECIST 1.1).
- 6 of 7 responses (including two
unconfirmed responses with no subsequent scan available at data
cut-off) were ongoing at data cut-off with longest response at
>12 months after infusion.
- mDOR was not reached (min 2.0+
months, max 11.5+ months) at a mFU of 4.8 months.
- Reduction of tumor size was
observed in 11 out of 12 patients, with a deepening of response
from initially stable disease (SD) to partial response (PR)
observed in two patients.
- Translational data showed enhanced
pharmacology of IMA203CD8 GEN2: trend towards responses at lower T
cell dose and higher tumor burden compared to IMA203 GEN1;
IMA203CD8 GEN2 achieved higher peak expansion (Cmax) when
normalized to infused dose and T cells showed higher initial
activation levels without exhaustion over time.
Development path for IMA203 GEN1 and
IMA203CD8 GEN2 monotherapiesThe goal of Immatics’
development strategy is to make its cell therapies targeting PRAME
available to the broadest possible solid cancer patient population
with an initial focus on the US market. To achieve this, Immatics
has announced a three-step development strategy for leveraging the
full breadth of PRAME, a target that is highly expressed in various
solid cancers.
- Focus on IMA203 GEN1 in cutaneous
melanoma (potentially bundled with uveal melanoma), targeted to
enter a registration-enabling Phase 2 clinical trial in 2024.
Discussions with FDA to align on patient population, clinical trial
design and CMC aspects are ongoing under the RMAT designation
achieved for IMA203 GEN1 in multiple cancer types including
cutaneous and uveal melanoma. There are up to 3,300 HLA-A*02 and
PRAME-positive cutaneous and uveal melanoma last-line patients per
year in the US. An update on the clinical development plan is
expected in the first quarter of 2024.
- In parallel, commence dedicated
dose expansion cohorts for signal finding in ovarian and uterine
cancer, preferentially with IMA203CD8 GEN2. Enrollment of patients
with these cancer types is already ongoing. There are up to 9,000
HLA-A*02 and PRAME-positive ovarian and uterine last-line cancer
patients per year in the US.
- The development of a broader
tumor-agnostic label in PRAME-positive solid cancers, including in
NSCLC, triple-negative breast cancer, and others. This could
leverage the full potential of PRAME across multiple solid cancer
types.
TCR Bispecifics Programs
Immatics’ T cell engaging receptor (TCER®)
candidates are next-generation, half-life extended TCR Bispecific
molecules designed to maximize efficacy while minimizing toxicities
in patients through Immatics’ proprietary format using a
high-affinity TCR domain against the tumor target and a
low-affinity T cell recruiter binding to the T cell.
- TCER® IMA401
(MAGEA4/8) – The Phase 1 trial to evaluate safety,
tolerability and initial anti-tumor activity of TCER® IMA401 in
patients with recurrent and/or refractory solid tumors is ongoing.
IMA401 targets an HLA-A*02:01-presented peptide that occurs
identically in two different proteins, MAGEA4 and MAGEA8. This
target peptide has been selected based on natural expression in
native solid tumors at particularly high target density (peptide
copy number per tumor cell identified by Immatics’ proprietary
quantitative mass spectrometry engine XPRESIDENT®). MAGEA4 and
MAGEA8 are expressed in multiple solid cancers including lung
cancer, head and neck cancer, melanoma, ovarian cancer, sarcoma and
others. IMA401 is being developed in collaboration with Bristol
Myers Squibb. First clinical data is expected to be announced in
2024.
- TCER® IMA402
(PRAME) – Immatics initiated the Phase 1/2 trial
investigating the company’s fully owned TCER® candidate IMA402 in
patients with recurrent and/or refractory solid tumors in August
and dosed the first patients. Initial focus indications are ovarian
cancer, lung cancer, uterine cancer, and cutaneous and uveal
melanoma, among others. IMA402 targets an HLA-A*02:01-presented
peptide derived from the tumor antigen PRAME. This target peptide
has been selected based on natural expression in native solid
primary tumors and metastases at particularly high target density
(peptide copy number per tumor cell identified by Immatics’
proprietary quantitative mass spectrometry engine XPRESIDENT®). An
update with first clinical data on TCER® IMA402 is anticipated in
2024.
Corporate Developments
On September 11, Immatics announced a strategic
multi-platform collaboration with Moderna, combining Immatics’
target and TCR platforms with Moderna’s cutting-edge mRNA
technology. The collaboration spans various therapeutic modalities
including bispecifics, cell therapy and cancer vaccines. Under the
terms of the agreement, Immatics received an upfront payment of
$120 million. In addition, Immatics will receive research funding
and is eligible to receive development, regulatory and commercial
milestone payments that could exceed $1.7 billion. Immatics is also
eligible to receive tiered royalties on global net sales of TCER®
products and certain vaccine products that are commercialized under
the agreement. Under the agreement, Immatics has an option to enter
into a global profit and loss share arrangement for the most
advanced TCER®. The strategic R&D collaboration between Moderna
and Immatics focuses on three pillars:
- Applying Moderna’s mRNA technology
for in vivo expression of Immatics’ next-generation, half-life
extended TCR Bispecifics (TCER®) targeting cancer-specific
HLA-presented peptides.
- Enabling the discovery and
development of novel mRNA-based cancer vaccines by leveraging
Moderna’s mRNA science and customized information from Immatics’
target discovery platform XPRESIDENT® and its bioinformatics and AI
platform XCUBE™.
- Evaluating Immatics’ IMA203 TCR-T
therapy targeting PRAME in combination with Moderna’s PRAME
mRNA-based cancer vaccine. The collaboration contemplates
conducting preclinical studies and a Phase 1 clinical trial
evaluating the safety and efficacy of the combination with the
objective of further enhancing IMA203 T cell responses.
On July 24, 2023, Bristol Myers Squibb purchased
2,419,818 ordinary shares in a private placement transaction at a
subscription price per share of $14.461. Pursuant to their rights
under the agreement, Bristol Myers Squibb appointed Anne Kerber,
M.D., Senior Vice President, Head of Cell Therapy Development at
Bristol Myers Squibb, to the Immatics Scientific Advisory Board
(SAB).
Third Quarter 2023 Financial Results
Cash Position: Cash and cash equivalents as well
as other financial assets total €366.0 million ($387.7 million2) as
of September 30, 2023, compared to €362.2 million ($383.7 million2)
as of December 31, 2022. The increase is mainly due to the opt-in
payment for one TCR-T candidate received from Bristol Myers Squibb
and equity raised in the period, partially offset by our ongoing
research and development activities and does not include the
upfront payment of $120 million received from Moderna in October
2023. The company projects a cash runway well into 2026.
Revenue: Total revenue, consisting of revenue
from collaboration agreements, was €5.9 million ($6.3 million2) for
the three months ended September 30, 2023, compared to €15.1
million ($16.0 million2) for the three months ended September 30,
2022. The decrease is mainly related to lower non-cash recognition
of deferred revenue from initial upfront payments.
Research and Development Expenses: R&D
expenses were €30.5 million ($32.3 million2) for the three months
ended September 30, 2023, compared to €28.6 million ($30.3
million2) for the three months ended September 30, 2022. The
increase mainly resulted from higher costs associated with the
advancement of the clinical pipeline of ACTengine® IMA203 and TCER®
IMA401 and IMA402 candidates.
General and Administrative Expenses: G&A
expenses were €8.9 million ($9.4 million2) for the three months
ended September 30, 2023, compared to €8.4 million ($8.9 million2)
for the three months ended September 30, 2022.
Net Profit and Loss: Net loss was €26.5 million
($28.1 million2) for the three months ended September 30, 2023,
compared to a net loss of €20.9 million ($22.1 million2) for the
three months ended September 30, 2022. The increased net loss
mainly resulted from lower non-cash revenue recognition.
Upcoming Investor Conferences
- Jefferies London Healthcare
Conference, London, U.K. – November 14-16, 2023
- Leerink Partners Global Biopharma
Conference, Miami, FL – March 11-13, 2024
- Jefferies Biotech on the Bay Miami
Summit, Miami, FL – March 12-13, 2024
To see the full list of events and presentations, visit
https://investors.immatics.com/events-presentations.
- END -
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
Immatics intends to use its website
www.immatics.com as a means of disclosing material non-public
information. For regular updates, you can also follow us on X,
Instagram and LinkedIn.
Forward-Looking
Statements:Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or the Company’s future financial
or operating performance. For example, statements concerning timing
of data read-outs for product candidates, the timing and outcome of
clinical trials, the nature of clinical trials (including whether
such clinical trials will be registration-enabling), the timing of
IND or CTA filing for pre-clinical stage product candidates,
estimated market opportunities of product candidates, the Company’s
focus on partnerships to advance its strategy, and other metrics
are forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as “may”, “should”,
“expect”, “plan”, “target”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable, Immatics and its management, are inherently uncertain.
New risks and uncertainties may emerge from time to time, and it is
not possible to predict all risks and uncertainties. Factors that
may cause actual results to differ materially from current
expectations include, but are not limited to, various factors
beyond management's control including general economic conditions
and other risks, uncertainties and factors set forth in the
Company’s Annual report on Form 20-F and other filings with the
Securities and Exchange Commission (SEC). Nothing in this press
release should be regarded as a representation by any person that
the forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. The Company undertakes no duty to update these
forward-looking statements. All the scientific and clinical data
presented within this press release are – by definition prior to
completion of the clinical trial and a clinical study report –
preliminary in nature and subject to further quality checks
including customary source data verification.
For more information, please
contact:
Media |
Eva Mulder or Charlotte Spitz |
|
Trophic Communications |
|
Phone: +31 65 2331 579 |
|
immatics@trophic.eu |
|
Investor Relations |
|
Sabrina Schecher, Ph.D. |
|
Senior Director, Investor Relations |
|
Phone: +49 89 262002433 |
|
InvestorRelations@immatics.com |
|
Unaudited Interim Condensed Consolidated Statement of
Profit/(Loss) of Immatics N.V.
|
Three months ended September 30,
|
Nine months ended September 30, |
|
2023 |
2022 |
2023 |
2022 |
|
(Euros in thousands, exceptper share
data) |
(Euros in thousands, exceptper
share data) |
Revenue from collaboration
agreements |
5,926 |
15,060 |
38,076 |
135,183 |
Research and development
expenses |
(30,498) |
(28,572) |
(85,396) |
(78,933) |
General and administrative
expenses |
(8,881) |
(8,422) |
(27,825) |
(26,383) |
Other income |
186 |
9 |
1,134 |
42 |
|
|
|
|
|
Operating
result |
(33,267) |
(21,925) |
(74,011) |
29,909 |
Change in fair value of liabilities for
warrants |
(1,395) |
(5,865) |
(7,103) |
7,877 |
Other financial
income |
9,748 |
7,839 |
14,414 |
16,613 |
Other financial
expenses |
(1,575) |
(426) |
(4,146) |
(1,950) |
|
|
|
1,548 |
|
Financial
result |
6,778 |
1,548 |
3,165 |
22,540 |
|
|
|
|
|
Profit/(loss) before
taxes |
(26,489) |
(20,377) |
(70,846) |
52,449 |
Taxes on
income |
— |
(558) |
— |
(1,703) |
Net
profit/(loss) |
(26,489) |
(20,935) |
(70,846) |
50,746 |
|
|
|
|
|
Net profit/(loss) per
share: |
|
|
|
|
Basic |
(0.32) |
(0.32) |
(0.90) |
0.79 |
Diluted |
(0.32) |
(0.32) |
(0.90) |
0.78 |
Unaudited Interim Condensed Consolidated Statement of
Comprehensive Income/(Loss) of Immatics N.V.
|
Three months ended September 30,
|
Nine months ended September 30,
|
|
2023 |
2022 |
2023 |
2022 |
|
(Euros in thousands) |
(Euros in thousands) |
Net
profit/(loss) |
(26,489) |
(20,935) |
(70,846) |
50,746 |
Other comprehensive income/(loss) |
|
|
|
|
Items that may be reclassified subsequently to profit or
loss |
|
|
|
|
Currency translation differences from foreign
operations |
429 |
(211) |
769 |
1,127 |
|
|
|
|
|
Total comprehensive income/(loss) for the
year |
(26,060) |
(21,146) |
(70,077) |
51,873 |
|
|
|
|
|
Unaudited Interim Condensed Consolidated Statement of
Financial Position of Immatics N.V.
|
|
|
|
As of |
|
September 30,2023
|
December 31,2022 |
|
|
|
|
(Euros in thousands) |
Assets |
|
|
Current assets |
|
|
Cash and cash
equivalents |
83,446 |
148,519 |
Other financial
assets |
282,574 |
213,686 |
Accounts
receivables |
514 |
1,111 |
Other current
assets |
18,473 |
13,838 |
|
|
|
Total current assets |
385,007 |
377,154 |
Non-current assets |
|
|
Property, plant and
equipment |
34,847 |
13,456 |
Intangible
assets |
1,633 |
1,632 |
Right-of-use assets
|
14,302 |
13,033 |
Other non-current
assets |
1,661 |
2,545 |
|
|
|
Total non-current
assets |
52,443 |
30,666 |
|
|
|
Total assets |
437,450 |
407,820 |
|
|
|
Liabilities and shareholders’ equity |
|
|
Current liabilities |
|
|
Provisions |
4,851 |
- |
Accounts
payables |
19,829 |
13,056 |
Deferred
revenue |
62,049 |
64,957 |
Liabilities for
warrants |
24,017 |
16,914 |
Lease
liabilities |
2,789 |
2,159 |
Other current
liabilities |
7,613 |
9,366 |
|
|
|
Total current liabilities |
121,148 |
106,452 |
Non-current liabilities |
|
|
Deferred
revenue |
54,860 |
75,759 |
Lease
liabilities |
13,671 |
12,403 |
Other non-current
liabilities |
20 |
42 |
|
|
|
Total non-current liabilities |
68,551 |
88,204 |
Shareholders’ equity |
|
|
Share capital |
847 |
767 |
Share premium |
818,761 |
714,177 |
Accumulated
deficit |
(571,145) |
(500,299) |
Other reserves |
(712) |
(1,481) |
|
|
|
Total shareholders’ equity |
247,751 |
213,164 |
|
|
|
Total liabilities and shareholders’ equity |
437,450 |
407,820 |
|
|
|
Unaudited Interim Condensed Consolidated Statement of
Cash Flows of Immatics N.V.
|
|
|
|
Nine months ended September 30,
|
|
2023 |
2022 |
|
|
|
|
(Euros in thousands) |
Cash flows from operating activities |
|
|
Net
profit/(loss) |
(70,846) |
50,746 |
Taxes on
income |
— |
1,703 |
Profit/(loss) before
tax |
(70,846) |
52,449 |
Adjustments for: |
|
|
Interest
income |
(8,993) |
(606) |
Depreciation and
amortization |
5,432 |
5,218 |
Interest
expenses |
620 |
748 |
Equity-settled share-based
payment |
16,299 |
16,725 |
Net foreign exchange differences and expected credit
losses |
(760) |
(11,974) |
Change in fair value of liabilities for
warrants |
7,103 |
(7,877) |
Changes in: |
|
|
Decrease/(increase) in accounts
receivables |
596 |
(457) |
Decrease/(increase) in other
assets |
658 |
(6,523) |
(Decrease)/increase in deferred revenue, accounts payables and
other
liabilities |
(15,641) |
84,185 |
Interest
received |
4,904 |
213 |
Interest paid |
(221) |
(521) |
Income tax
paid |
— |
— |
|
|
|
Net cash (used in)/provided by operating
activities |
(60,849) |
131,580 |
|
|
|
Cash flows from investing activities |
|
|
Payments for property, plant and
equipment |
(21,506) |
(3,390) |
Payments for intangible
assets |
(158) |
(220) |
Proceeds from disposal of property, plant and
equipment |
— |
53 |
Payments for investments classified in Other financial
assets |
(299,018) |
(128,726) |
Proceeds from maturity of investments classified in Other financial
assets |
229,557 |
12,695 |
|
— |
— |
Net cash (used in)/provided by investing
activities |
(91,125) |
(119,588) |
|
|
|
Cash flows from financing activities |
|
|
Proceeds from issuance of shares to equity
holders |
90,404 |
21,009 |
Transaction costs deducted from
equity |
(2,039) |
(626) |
Repayment of lease
liabilities |
(2,877) |
(2,162) |
|
|
|
Net cash provided by/(used in) financing
activities |
85,488 |
18,221 |
|
|
|
Net (decrease)/increase in cash and cash
equivalents |
(66,486) |
30,213 |
|
|
|
Cash and cash equivalents at beginning of the
year |
148,519 |
132,994 |
|
|
|
Effects of exchange rate changes and expected credit losses on cash
and cash
equivalents |
1,413 |
14,840 |
|
|
|
Cash and cash equivalents at end of the
year |
83,446 |
178,047 |
Unaudited Interim Condensed Consolidated Statement of
Changes in Shareholders’ equity of Immatics N.V.
|
|
|
|
|
|
(Euros
in thousands) |
Sharecapital |
Sharepremium |
Accumulateddeficit |
Otherreserves |
Totalshare-holders’equity
|
Balance as of January 1,
2022 |
629 |
565,192 |
(537,813) |
(3,945) |
24,063 |
Other comprehensive
income |
— |
— |
— |
1,127 |
1,127 |
Net profit |
— |
— |
50,746 |
— |
50,746 |
Comprehensive income for the
year |
— |
— |
50,746 |
1,127 |
51,873 |
Equity-settled share-based
compensation |
— |
16,725 |
— |
— |
16,725 |
Share options
exercised |
— |
202 |
— |
— |
202 |
Issue of share capital – net of transaction
costs |
28 |
20,153 |
— |
— |
20,181 |
|
|
|
|
|
|
Balance as of September 30, 2022 |
657 |
602,272 |
(487,067) |
(2,818) |
113,044 |
|
|
|
|
|
|
Balance as of January 1,
2023 |
767 |
714,177 |
(500,299) |
(1,481) |
213,164 |
Other comprehensive
income |
— |
— |
— |
769 |
769 |
Net loss |
— |
— |
(70,846) |
— |
(70,846) |
Comprehensive loss for the
year |
— |
— |
(70,846) |
769 |
(70,077) |
Equity-settled share-based
compensation |
— |
16,299 |
— |
— |
16,299 |
Share options
exercised |
— |
140 |
— |
— |
140 |
Issue of share capital – net of transaction
costs |
80 |
88,145 |
— |
— |
88,225 |
|
|
|
|
|
|
Balance as of September 30, 2023 |
847 |
818,761 |
(571,145) |
(712) |
247,751 |
|
|
|
|
|
|
1 Exact price per share $14.4639 2 All amounts translated using
the exchange rate published by the European Central Bank in effect
as of September 30, 2023 (1 EUR = 1.0594 USD).
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Oct 2023 to Oct 2024